Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Kyverna Therapeutics, Inc. regarding a class action lawsuit related to the company's initial public offering (IPO) in February 2024, alleging misleading statements and omissions in the offering documents [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals who purchased or acquired Kyverna common stock during the class period associated with the February 2024 IPO [2]. - Allegations include that the defendants issued materially false and misleading statements and failed to disclose critical information regarding the IPO strategy, terms, and disclosures in the offering documents [3]. - The complaint suggests that the underwriter defendants should have been aware of Kyverna's undisclosed issues due to ongoing communications with the company's management and legal representatives [3]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by February 7, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].
Contact The Gross Law Firm by February 7, 2025 Deadline to Join Class Action Against Kyverna Therapeutics, Inc.(KYTX)